Indaptus Therapeutics News

Indaptus Therapeutics Analyst Ratings

BenzingaJun 17 06:41 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cingulate Inc (CING), Indaptus Therapeutics (INDP) and Immunocore Holdings (IMCR)

TipRanksMay 24 12:15 ET

Buy Rating Affirmed for Indaptus Therapeutics Amid Promising Decoy20 Clinical Advancements

TipRanksMay 9 13:00 ET

Indaptus Therapeutics Analyst Ratings

BenzingaApr 15 06:11 ET

Buy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough With Decoy20 Platform

TipRanksApr 12 15:10 ET

Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial Outlook

TipRanksMar 14 14:00 ET

Buy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 With Promising Developments

TipRanksMar 6 14:20 ET

Analysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP)

TipRanksNov 7, 2023 09:50 ET

Indaptus Therapeutics: Promising Phase 1 Results and Optimistic Valuation Bolster Buy Rating

TipRanksNov 3, 2023 06:39 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), Myriad Genetics (MYGN) and Indaptus Therapeutics (INDP)

TipRanksSep 20, 2023 06:32 ET

Indaptus Therapeutics Analyst Ratings

BenzingaSep 20, 2023 06:32 ET

Analysts' Top Healthcare Picks: Indaptus Therapeutics (INDP), Achieve Life Sciences (ACHV)

TipRanksAug 15, 2023 11:30 ET

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

BenzingaAug 15, 2023 06:55 ET

Indaptus Therapeutics Analyst Ratings

BenzingaAug 15, 2023 06:55 ET

H.C. Wainwright Sticks to Its Buy Rating for Indaptus Therapeutics (INDP)

TipRanksAug 15, 2023 06:35 ET

Maxim Group Remains a Buy on Indaptus Therapeutics (INDP)

TipRanksAug 11, 2023 11:25 ET

Indaptus Therapeutics Analyst Ratings

BenzingaAug 11, 2023 07:13 ET

Indaptus Therapeutics (INDP) Receives a Buy From H.C. Wainwright

TipRanksAug 8, 2023 06:25 ET

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

BenzingaAug 8, 2023 06:20 ET

Indaptus Therapeutics Analyst Ratings

BenzingaAug 8, 2023 06:19 ET